VEGFA and non-small cell lung carcinoma: Taking all these data into consideration, it was concluded that the increase in Ang-2 in 16 NSCLC patients after three cycles of treatment with platinum-based chemotherapy and anti-VEGF might be related to the role of Ang-2 in resistance to anti-VEGF therapy.